The European influenza vaccine market is evaluated to register a CAGR of 6.43% during the forecast period of 200-2028. A surge in government funding and the increasing spending by the market players are creating lucrative market opportunities in the region. The Europe influenza vaccine market is further researched by segmenting the region into countries such as Germany, Italy, Russia, Poland, the UK, Belgium, France, and the rest of Europe.
EUROPE INFLUENZA VACCINE MARKET FORECAST 2020-2028
Europe Influenza Vaccine Market by Type (Quadrivalent Vaccine, Trivalent Vaccine) by Technology (Egg-based Technology, Cell-based Technology) by Age Group (Pediatric Age Group, Adult Age Group) by Delivery Mode (Injection, Asal Spray) and by Geography.
The European influenza vaccine market is evaluated to register a CAGR of 6.43% during the forecast period of 200-2028. A surge in government funding and the increasing spending by the market players are creating lucrative market opportunities in the region.
The Europe influenza vaccine market is further researched by segmenting the region into countries such as Germany, Italy, Russia, Poland, the UK, Belgium, France, and the rest of Europe. In the UK, low to moderate rates of influenza were observed from 2018 to 2019. Influenza transmission created a high impact on secondary care with regard to hospitalization and ICU admissions. The rates of hospitalization and ICU were somewhat lower than in 2017-2018, but higher than all seasons since 2010-2011. Mortality rates were lowest since 2013-2014 in England, but Scotland and Northern Ireland observed significant mortality. In countries like Germany, approximately 3.8 million iMAARI cases occurred, which is considerably lower as compared to previous epidemic seasons.
France is in a situation of influenza epidemic since the beginning of February 2020. All the regions of the country are in a state of the epidemic, with 175 out of 100,000 people falling sick, except the greater Paris Ile-de-France, which is post epidemic. In Italy, 2,768,000 cases were confirmed by laboratory tests all over the country since October 2019. The flu season was at its peak in January, and 240 deaths were reported. The vaccination is recommended for people above 60, pregnant women, the chronically ill, and the health workers. These factors will help the market grow in the region.
Sanofi is a healthcare company involved in the development, research, manufacture, and marketing of innovative therapeutic solutions. In May 1999, Sanofi and Synthelabo merged to create a new major pharmaceutical company.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES `
- MARKET OVERVIEW
- MARKET DYNAMICS
- PARENT MARKET ANALYSIS: VACCINE MARKET
- MARKET DEFINITION
- KEY DRIVERS
- GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
- RISE IN THE CASES OF INFLUENZA
- TECHNOLOGY ADVANCEMENT
- KEY RESTRAINTS
- HIGH COST OF DEVELOPMENT
- LENGTHY PROCESS OF DEVELOPMENT
- KEY ANALYTICS
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- BUYER POWER
- SUPPLIER POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- MARKET BY TYPE
- QUADRIVALENT VACCINE
- TRIVALENT VACCINE
- MARKET BY TECHNOLOGY
- EGG-BASED TECHNOLOGY
- CELL-BASED TECHNOLOGY
- MARKET BY AGE GROUP
- PEDIATRIC AGE GROUP
- ADULT AGE GROUP
- MARKET BY DELIVERY MODE
- INJECTION
- NASAL SPRAY
- GEOGRAPHICAL ANALYSIS
- EUROPE
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- EUROPE
- COMPANY PROFILES
- MERCK
- NOVARTIS AG
- PFIZER INC
- SANOFI
- BIODIEM
- EMERGENT BIOSOLUTIONS
- HOFFMANN-LA ROCHE LTD
- GLAXOSMITHKLINE
- ABBOTT
- CSL LTD
TABLE LIST
TABLE 1: MARKET SNAPSHOT – INFLUENZA VACCINE
TABLE 2: EUROPE INFLUENZA VACCINE MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 3: EUROPE INFLUENZA VACCINE MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 4: EUROPE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: EUROPE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: EUROPE INFLUENZA VACCINE MARKET, BY AGE GROUP, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: EUROPE INFLUENZA VACCINE MARKET, BY AGE GROUP, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: EUROPE INFLUENZA VACCINE MARKET, BY DELIVERY MODE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: EUROPE INFLUENZA VACCINE MARKET, BY DELIVERY MODE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
FIGURES LIST
FIGURE 1: KEY INVESTMENT INSIGHTS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: VENDOR LANDSCAPE
FIGURE 5: EUROPE INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2019
FIGURE 6: EUROPE INFLUENZA VACCINE MARKET, BY QUADRIVALENT VACCINE, 2020-2028 (IN $ MILLION)
FIGURE 7: EUROPE INFLUENZA VACCINE MARKET, BY TRIVALENT VACCINE, 2020-2028 (IN $ MILLION)
FIGURE 8: EUROPE INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2019
FIGURE 9: EUROPE INFLUENZA VACCINE MARKET, BY EGG-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 10: EUROPE INFLUENZA VACCINE MARKET, BY CELL-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 11: EUROPE INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY AGE GROUP, IN 2019
FIGURE 12: EUROPE INFLUENZA VACCINE MARKET, BY PEDIATRIC AGE GROUP, 2020-2028 (IN $ MILLION)
FIGURE 13: EUROPE INFLUENZA VACCINE MARKET, BY ADULT AGE GROUP, 2020-2028 (IN $ MILLION)
FIGURE 14: EUROPE INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY DELIVERY MODE, IN 2019
FIGURE 15: EUROPE INFLUENZA VACCINE MARKET, BY INJECTION, 2020-2028 (IN $ MILLION)
FIGURE 16: EUROPE INFLUENZA VACCINE MARKET, BY NASAL SPRAY, 2020-2028 (IN $ MILLION)
FIGURE 17: EUROPE INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 18: UNITED KINGDOM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 19: GERMANY INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 20: FRANCE INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 21: ITALY INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 22: RUSSIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 23: BELGIUM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 24: POLAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
FIGURE 25: REST OF EUROPE INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- EUROPE
- MARKET BY TYPE
- QUADRIVALENT VACCINE
- TRIVALENT VACCINE
- MARKET BY TECHNOLOGY
- EGG-BASED TECHNOLOGY
- CELL-BASED TECHNOLOGY
- MARKET BY AGE GROUP
- PEDIATRIC AGE GROUP
- ADULT AGE GROUP
- MARKET BY DELIVERY MODE
- INJECTION
- NASAL SPRAY
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.